LONDON, June 11, 2014 /PRNewswire/ --
The US markets on Tuesday, June 10, 2014 ended on a mixed note as the Dow Jones
Industrial Average finished at 16,945.92, up 0.02% and the NASDAQ Composite closed at
4,338.00, up 0.04%. The S&P 500 finished the session 0.02% lower at 1,950.79. During the
trading session, four out of ten sectors finished on a higher note. The S&P 500 Health
Care Sector Index ended the day at 692.83, up 0.21%, with the index advancing 3.66% in the
last one month. Investor-Edge has initiated coverage on the following equities: Isis
Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Amarin Corp. PLC
(NASDAQ: AMRN) and Prana Biotechnology Ltd (NASDAQ: PRAN). Free technical research on
ISIS, PCYC, AMRN and PRAN can be downloaded upon signing up at:
On Tuesday, shares in Isis Pharmaceuticals Inc. fluctuated between $32.30 and $34.20
before ending the session 9.84% higher at $34.17. The stock reported a trading volume of
5.19 million shares, much above its three months average volume of 2.66 million shares.
Isis Pharmaceuticals Inc.'s shares have rallied 12.96% in the previous three sessions and
45.90% in the last one month, while the stock has lost 14.23% on YTD basis. The stock is
trading above its 50-day moving average of $30.89, while the 50-day moving average is
below its 200-day moving average of $37.71. Moreover, shares of Isis Pharmaceuticals Inc.
have a Relative Strength Index (RSI) of 57.98. On the same day, Isis Pharmaceuticals Inc.
announced that AstraZeneca has initiated a Phase 1 clinical study of its antisense drug,
ISIS-ARRx in patients with cancer. The company has also received payment of $15 million in
association with the clinical advancement of ISIS-ARRx. Sign up today to read free
research on ISIS at:
On Tuesday, Pharmacyclics Inc.'s stock edged 0.42% lower, to close the day at $96.67.
The stock recorded a trading volume of 1.07 million shares, below its three months average
volume of 1.59 million shares. The stock oscillated between $94.19 and $98.78 during the
session. Over the last three trading sessions and over the past one month, Pharmacyclics
Inc.'s shares have gained 2.77% and 1.67%, respectively. However, the stock has lost 8.61%
since the start of this year. The stock is trading above its 50-day moving average of
$94.77, while the 200-day moving averages of $117.33 is above its 50-day moving average.
Additionally, Pharmacyclics Inc.'s stock traded at a PE ratio of 54.93 and has an RSI of
54.58. Sign up today to read free research on PCYC at:
On Tuesday, shares in Amarin Corp. PLC recorded a trading volume of 0.85 million
shares, lower than its three months average volume of 1.90 million shares. The stock ended
the day at the previous day's closing price of $1.50, and registered an intraday range of
$1.49 and $1.52. Although Amarin Corp. PLC's stock has gained 4.17% in the previous three
trading sessions, it has lost 0.66% in the last one month and 23.86% on YTD basis. The
company's stock is trading below its 50-day and 200-day moving averages of $1.57 and
$2.67, respectively. Furthermore, shares of Amarin Corp. PLC have an RSI of 53.65. Sign up
today to read free research on AMRN at:
Prana Biotechnology Ltd's stock finished the Tuesday's session 6.84% higher at $2.03.
A total of 1.47 million shares were traded, which was below its three months average
volume of 1.98 million shares. The stock vacillated between $1.88 and $2.05 during the
session. Over the previous three trading sessions and over the last one month, Prana
Biotechnology Ltd's shares have surged 14.69% and 20.83%, respectively. However, from the
beginning of 2014, the company's stock has declined 71.04%. The company's shares are
trading above their 50-day moving average. Moreover, the stock's 200-day moving average of
$5.48 is greater than its 50-day moving average of $2.02. Shares of Prana Biotechnology
Ltd have an RSI of 45.98. Sign up today to read free research on PRAN at:
1. This is not company news. We are an independent source and our views do not reflect
the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a
CFA charterholder. The content is then further fact checked and reviewed by an outsourced
research provider. However, we are only human and are prone to make mistakes. If you
notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase
awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to
learn more about our services, please contact us at pubco [at]
5. For any urgent concerns or inquiries, please contact us at compliance [at]
6. Are you a public company? Would you like to see similar coverage on your company?
Send us a full investors' package to research [at] http://www.investor-edge.com for
Content is researched, written and reviewed on a best-effort basis. This document, article
or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An
outsourced research services provider has only reviewed the information provided by
Investor-Edge in this article or report according to the procedures outlined by
Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or reports, as the
case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness
or fitness for a purpose (investment or otherwise), of the information provided in this
document. This information is not to be construed as personal financial advice. Readers
are encouraged to consult their personal financial advisor before making any decisions to
buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake or shortcoming. No liability is accepted
by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from
the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility
or liability for any consequences, financial or otherwise arising from any reliance placed
on the information in this document. Investor-Edge does not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information, or (2) warrant any
results from use of the information. The included information is subject to change without
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA